Anti-CD25 monoclonal antibodies (e.g., daclizumab, baliximab, etc.)have been shown to target CD25+ Tregs, thereby enhancing tumor immunity and immunotherapy [184,185], and daclizumab also significantly eliminates CD4+CD25+ Tregs from peripheral blood within 3–4 weeks and restores the Treg phenotype within 8 weeks [186]. Here, IL2RA is linked to neoplasm.